Erding Hu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11680340/publications.pdf Version: 2024-02-01



FRDING HU

#	Article	IF	CITATIONS
1	Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell, 1994, 79, 1147-1156.	28.9	3,322
2	AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity. Journal of Biological Chemistry, 1996, 271, 10697-10703.	3.4	1,885
3	Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor Î ³ . Current Opinion in Genetics and Development, 1995, 5, 571-576.	3.3	426
4	Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR7 and RXRa. Nucleic Acids Research, 1994, 22, 5628-5634.	14.5	352
5	Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 720-728.	2.5	347
6	Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription Repressor. Journal of Biological Chemistry, 2000, 275, 15254-15264.	3.4	244
7	Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovascular Research, 2004, 61, 548-558.	3.8	200
8	Adipocyte differentiation: a transcriptional regulatory cascade. Current Opinion in Cell Biology, 1996, 8, 826-832.	5.4	171
9	Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 89-98.	2.5	142
10	Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 6-9.	6.4	139
11	Expression and functional role of Rhoâ€kinase in rat urinary bladder smooth muscle. British Journal of Pharmacology, 2003, 138, 757-766.	5.4	138
12	Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Letters, 2002, 188, 127-140.	7.2	88
13	Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat. Journal of Cardiovascular Pharmacology, 2010, 56, 147-155.	1.9	84
14	Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opinion on Therapeutic Targets, 2005, 9, 715-736.	3.4	70
15	Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases. Journal of Medicinal Chemistry, 2008, 51, 6631-6634.	6.4	68
16	Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (CSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. Vascular Medicine, 2014, 19, 473-482.	1.5	39
17	Tissue Restricted Expression of Two Human Frzbs in Preadipocytes and Pancreas. Biochemical and Biophysical Research Communications, 1998, 247, 287-293.	2.1	38
18	DEF-1, a Novel Src SH3 Binding Protein That Promotes Adipogenesis in Fibroblastic Cell Lines. Molecular and Cellular Biology, 1999, 19, 2330-2337.	2.3	38

Erding Hu

#	Article	IF	CITATIONS
19	Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. American Journal of Physiology - Endocrinology and Metabolism, 2014, 306, E150-E156.	3.5	38
20	The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits. PLoS ONE, 2017, 12, e0184049.	2.5	27
21	Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases. Current Opinion in Investigational Drugs, 2003, 4, 1065-75.	2.3	16
22	Recent Patents on Rho Signaling Pathway as Therapeutic Target for Cardiovascular Diseases. Recent Patents on Cardiovascular Drug Discovery, 2006, 1, 249-263.	1.5	11
23	In Vivo Imaging of Small Molecular Weight Peptides for Targeted Renal Drug Delivery: A Study in Normal and Polycystic Kidney Diseased Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 786-795.	2.5	8
24	Brain-targeted hypoxia-inducible factor stabilization reduces neonatal hypoxic-ischemic brain injury. Neurobiology of Disease, 2021, 148, 105200.	4.4	8
25	Rapid Isolation of Tissue-Specific Genes from Rat Kidney. Nephron Experimental Nephrology, 2001, 9, 156-164.	2.2	4